Aspergillosis Treatment Market Report 2026

Aspergillosis Treatment Market Overview

• Aspergillosis Treatment market size has reached to $3.3 billion in 2025 • Expected to grow to $4.58 billion in 2030 at a compound annual growth rate (CAGR) of 7% • Growth Driver: Increasing Healthcare Expenditures Boosting The Aspergillosis Treatment Market • Market Trend: Innovative Aspergillosis Treatment Solutions Enhance Patient Care • North America was the largest region in 2025.

What Is Covered Under Aspergillosis Treatment Market?

Aspergillosis treatment refers to treating a fungal infection caused by the aspergillus species and its treatment depends on the severity and type of disease. Aspergillosis can be a severe and potentially life-threatening condition, especially in individuals with weakened immune systems. The main types of aspergillosis treatment are allergic aspergillosis, chronic aspergillosis, invasive aspergillosis and others. Allergic aspergillosis, also known as allergic bronchopulmonary aspergillosis (ABPA), is a specific type of allergic reaction to the Aspergillus fungus, most commonly caused by Aspergillus fumigatus. The various drug classes include corticosteroids, antifungal drugs and others. The multiple routes of administration include oral, injectable and others and are distributed through several distribution channels such as hospital pharmacies, retail pharmacies and others.

What Is The Aspergillosis Treatment Market Growth Forecast?

The aspergillosis treatment market size is expected to see strong growth in the next few years. It will grow to $4.58 billion in 2030 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to increasing research into resistant fungal strains, rising demand for personalized treatment approaches, expansion of antifungal drug pipelines, growing adoption of early diagnostic testing, increasing healthcare expenditure on infectious diseases. Major trends in the forecast period include increasing development of novel antifungal therapies, rising adoption of precision diagnostics for early detection, growing focus on targeted treatment protocols, expansion of combination antifungal therapies, enhanced monitoring of treatment outcomes.

Global Aspergillosis Treatment Market Segmentation

1) By Type: Allergic Aspergillosis, Chronic Aspergillosis, Invasive Aspergillosis 2) By Drug Class: Corticosteroids, Antifungal drugs, Other Drug Classes 3) By Route of Administration: Oral, Injectable, Other Routes Of Administration 4) By Distribution Channel: Hospital pharmacies, Retail pharmacies, Other Distribution Channels Subsegments: 1) By Allergic Aspergillosis: Allergic Fungal Sinusitis, Allergic Bronchopulmonary Aspergillosis (ABPA) 2) By Chronic Aspergillosis: Chronic Pulmonary Aspergillosis, Chronic Cavitary Aspergillosis 3) By Invasive Aspergillosis: Pulmonary Invasive Aspergillosis, Disseminated Invasive Aspergillosis

What Is The Driver Of The Aspergillosis Treatment Market?

The rise in healthcare expenditures is expected to propel the growth of the aspergillosis treatment market going forward. Health expenditures refer to all costs associated with providing health services, family planning activities, nutrition programs, and emergency help with a focus on health. A rise in healthcare expenditure would result in the development of more effective therapies and medical technologies for aspergillosis treatment. For instance, in May 2023, the Office for National Statistics, a UK-based statistics authority, reported that in 2023, healthcare expenditure in the UK was approximately $362.08 billion (£292 billion), reflecting a nominal increase of 5.6%. Therefore, the rise in healthcare expenditures is driving the growth of the aspergillosis treatment industry.

Key Players In The Global Aspergillosis Treatment Market

Major companies operating in the aspergillosis treatment market are Basilea Pharmaceutica Ltd., Pfizer Inc., Johnson and Johnson, AbbVie Inc., Bayer AG, Novartis AG, Merck and Co. Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries, Astellas Pharma Inc., Regeneron Pharmaceuticals, Mylan N.V. , Sun Pharmaceutical Industries, Jazz Pharmaceuticals, Dr. Reddy's Laboratories, Cipla Ltd., Hikma Pharmaceuticals PLC

Global Aspergillosis Treatment Market Trends and Insights

Major companies operating in the aspergillosis treatment market are focused on introducing innovative aspergillosis drugs and solutions to sustain their position in the market. Drug development increases treatment options for aspergillosis, such as posaconazole oral suspension, which provides more targeted and effective treatment options for patients. For instance, in April 2023, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical company, launched posaconazole oral suspension in the US for aspergillosis treatment. These drugs apply to patients at high risk of contracting invasive Aspergillus and Candida infections, as they have severely compromised immune systems, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD). Oropharyngeal candidiasis (OPC), especially OPC refractory (OPC) to itraconazole and fluconazole, is another condition for which posaconazole oral suspension is recommended.

What Are Latest Mergers And Acquisitions In The Aspergillosis Treatment Market?

In October 2023, Basilea Pharmaceutica Ltd, a Switzerland-based biopharma company, acquired assets from Gravitas Therapeutics Inc. for $2 million upfront, with additional milestone and royalty payments. Through this acquisition, Basilea aims to strengthen its aspergillosis treatment pipeline by integrating Gravitas’s clinical-stage antifungal GR 2397 (renamed BAL2062) and targeting invasive mold infections caused by Aspergillus species. Gravitas Therapeutics Inc. is a US-based biotech company that provides GR 2397, a novel antifungal compound with fungicidal activity against Aspergillus spp., including azole-resistant strains.

Regional Outlook

North America was the largest region in the aspergillosis treatment market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Aspergillosis Treatment Market?

The aspergillosis treatment market consists of sales of immunotherapy drugs, echinocandin and azole antifungals. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Aspergillosis Treatment Market Report 2026?

The aspergillosis treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the aspergillosis treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.